Mark Lowdell, Ph.D has been Co-founder and Chief Scientific Officer since the formation of INmuneBIO in September 2015. The company is an immunotherapy company developing treatments to reprogram the innate immune system to fight disease. Lowdell is also professor of Cell and Tissue Therapy at University College London, where he has led a translational immunotherapy group since 1994. Since February 2009, he has also been Director of Cellular Therapy at the Royal Free London NHS Foundation Trust. Professor Lowdell received his Ph.D in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.
Onco’Zine is raising awareness of the impact of cancer, cancer diagnosis and treatment an publishes a broad range of topics and timely news updates with information from all oncology disciplines and sub-specialties from around the world.